Prelude announces Lilly collaboration to evaluate PRT13722 in breast cancer

PRLD•2026-10-13

Prelude Therapeutics and Lilly agreed to collaborate on a Phase 1 trial evaluating PRT13722 with abemaciclib and imlunestrant in patients with HR+/HER2- breast cancer; enrollment is expected to begin in Q4 2026. Prelude retains full global development and commercial rights to PRT13722.

1. Trial collaboration

Prelude Therapeutics announced a clinical trial collaboration and supply agreement with Lilly to evaluate its KAT6A selective degrader PRT13722 in combination with abemaciclib and imlunestrant in patients with HR+/HER2- breast cancer. The companies expect enrollment in the Phase 1 trial to begin in Q4 2026, and Prelude retains full global development and commercial rights to PRT13722.

Prelude announces Lilly collaboration to evaluate PRT13722 in breast cancer

1. Trial collaboration

Related News

Wearable Devices to exhibit at Augmented Enterprise Summit, showcasing Mudra Studio Evaluation Kit

BIO-key names Stephen Morrow president of PortalGuard as Mark Cochran retires

Borr Drilling director Tor Olav Troim acquires $11.84 million in common shares

Skydance settles cash tender offers for $2.4 billion of WBD notes after acquisition closes

Fastea Capital flags SpaceX Starlink move as rising threat to telecom operators